{
      "Rank": 985,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) 1 x 10^6 cells/kg in normal saline injection",
            "Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) 3 x 10^6 cells/kg in normal saline injection",
            "5-25mg Methotrexate orally"
      ],
      "ArmGroupInterventionName": [
            "Biological: Low-dose UC-MSCs",
            "Biological: High-dose UC-MSCs",
            "Drug: Methotrexate"
      ],
      "ArmGroupLabel": [
            "Low-Dose UC-MSCs",
            "High-Dose UC-MSCs",
            "Methotrexate"
      ],
      "ArmGroupType": [
            "Experimental",
            "Experimental",
            "Active Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT03424629"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "This is a study in patients with moderate to severe chronic plaque psoriasis.All the participants will be randomized into three groups, high-dose UC-MSCs, low-dose UC-MSCs, or methotrexate group.This study is designed to prove that UC-MSCs is safe and effective."
      ],
      "BriefTitle": [
            "Safety and Efficacy of UC-MSCs in Patients With Plaque Psoriasis"
      ],
      "CentralContactEMail": [
            "zhangchunleius@163.com"
      ],
      "CentralContactName": [
            "Chunlei Zhang, doctor"
      ],
      "CentralContactPhone": [
            "86-13716014425"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact"
      ],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "December 31, 2019"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Moderate and Severe Plaque Psoriasis"
      ],
      "ConditionAncestorId": [
            "D000017444",
            "D000012871"
      ],
      "ConditionAncestorTerm": [
            "Skin Diseases, Papulosquamous",
            "Skin Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC17",
            "All"
      ],
      "ConditionBrowseBranchName": [
            "Skin and Connective Tissue Diseases",
            "All Conditions"
      ],
      "ConditionBrowseLeafAsFound": [
            "Psoriasis"
      ],
      "ConditionBrowseLeafId": [
            "M13574",
            "M14826",
            "M18865"
      ],
      "ConditionBrowseLeafName": [
            "Psoriasis",
            "Skin Diseases",
            "Skin Diseases, Papulosquamous"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000011565"
      ],
      "ConditionMeshTerm": [
            "Psoriasis"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Crossover Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "Psoriasis is a chronic, incurable, immune-mediated dermatological disease, and it is considered that immune system dysregulation is the important cause of the disease.Umbilical cord derived mesenchymal stem cells (UC-MSCs) have be proven safe and effective for the treatment of various intractable autoimmune and inflammatory disorders because of their distinct immunomodulatory properties.\n\nPatients will be randomized into three groups.In one group patients will be treated with 1x10^6 cells/kg in 0,1,2,3,5,7 week, in the second group patients will be treated with 3x10^6 cells/kg in 0,1,2,3,5,7 week,in the third group patients will be treated with 5-25mg Methotrexate from 0 to 15 week In this study, researchers will determine the safety of UC-MSCs that a patient can tolerate without causing side effects. Moreover researchers will also be assess the efficacy and sustainability of UC-MSCs in 52 weeks."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nMale or female patients \u226518 years old with moderate-to-severe psoriasis.\nDiagnosis of plaque psoriasis at least 6 months before entering the study.\nModerate-to-severe plaque psoriasis(PASI\u226510\uff0cor BSA\u226510% and DLQI score\u226510).\nFailure after conventional therapy.\nNo other treatment for psoriasis during the period of the trial.\nWilling and able to comply with all study requirements and provide informed consent.\n\nExclusion Criteria:\n\nOther types of psoriasis,such as pustular, erythrodermic and guttate psoriasis).\nDrug-induced psoriasis (i.e., new onset or current exacerbation from beta-blockers, calcium channel inhibitors or lithium).\nOngoing use of other psoriasis treatments.\nEver use of any biologic drug directly targeting IL-17,IL-23,TNFa etc.\nActive systemic infections during the last two weeks (exception: common cold) prior to initiation of the trial and any infections that reoccur on a regular basis.\nHistory of malignancy .\nEvidence of infection with HIV, hepatitis B or hepatitis C.\nPregnant or lactating females, or willing to have a baby during the trial.\nCan not be traced on time."
      ],
      "EnrollmentCount": [
            "57"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000000020",
            "D000000019",
            "D000012102",
            "D000045505",
            "D000000964",
            "D000000963",
            "D000045504",
            "D000000970",
            "D000003879",
            "D000004791",
            "D000005493",
            "D000007166",
            "D000007155",
            "D000018501",
            "D000019384"
      ],
      "InterventionAncestorTerm": [
            "Abortifacient Agents, Nonsteroidal",
            "Abortifacient Agents",
            "Reproductive Control Agents",
            "Physiological Effects of Drugs",
            "Antimetabolites, Antineoplastic",
            "Antimetabolites",
            "Molecular Mechanisms of Pharmacological Action",
            "Antineoplastic Agents",
            "Dermatologic Agents",
            "Enzyme Inhibitors",
            "Folic Acid Antagonists",
            "Immunosuppressive Agents",
            "Immunologic Factors",
            "Antirheumatic Agents",
            "Nucleic Acid Synthesis Inhibitors"
      ],
      "InterventionArmGroupLabel": [
            "Low-Dose UC-MSCs",
            "High-Dose UC-MSCs",
            "Methotrexate"
      ],
      "InterventionBrowseBranchAbbrev": [
            "ANeo",
            "ARhu",
            "Derm",
            "Repr",
            "All",
            "Micro",
            "Hemat",
            "Vi"
      ],
      "InterventionBrowseBranchName": [
            "Antineoplastic Agents",
            "Antirheumatic Agents",
            "Dermatologic Agents",
            "Reproductive Control Agents",
            "All Drugs and Chemicals",
            "Micronutrients",
            "Hematinics",
            "Vitamins"
      ],
      "InterventionBrowseLeafAsFound": [
            "Into"
      ],
      "InterventionBrowseLeafId": [
            "M10855",
            "M3433",
            "M6226",
            "M7770",
            "M16698",
            "M7771",
            "M9364",
            "M9353",
            "M19757",
            "T447",
            "T446",
            "T448",
            "T475"
      ],
      "InterventionBrowseLeafName": [
            "Methotrexate",
            "Antimetabolites",
            "Dermatologic Agents",
            "Folic Acid",
            "Vitamin B Complex",
            "Folic Acid Antagonists",
            "Immunosuppressive Agents",
            "Immunologic Factors",
            "Antirheumatic Agents",
            "Folinic Acid",
            "Folic Acid",
            "Folate",
            "Vitamin B9"
      ],
      "InterventionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "Participants will receive 6 times UC-MSCs infusions (each time 1\u00d710^6/kg). The first time to fourth time will be given once a week for successive 4 weeks\uff08week 0,1,2,3\uff09, then the last two times will be given once every two weeks\uff08week 5,7\uff09.",
            "Participants will receive 6 times UC-MSCs infusions (each time 3\u00d710^6/kg). The first time to fourth time will be given once a week for successive 4 weeks\uff08week 0,1,2,3\uff09, then the last two times will be given once every two weeks\uff08week 5,7\uff09.",
            "Participants will be administered Methotrexate (each time 5-25mg) orally once a week for successive 16 weeks(week 0-15)."
      ],
      "InterventionMeshId": [
            "D000008727"
      ],
      "InterventionMeshTerm": [
            "Methotrexate"
      ],
      "InterventionName": [
            "Low-dose UC-MSCs",
            "High-dose UC-MSCs",
            "Methotrexate"
      ],
      "InterventionOtherName": [
            "regenskin",
            "regenskin"
      ],
      "InterventionType": [
            "Biological",
            "Biological",
            "Drug"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "psoriasis",
            "UC-MSCs"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [
            "Not yet recruiting"
      ],
      "LastUpdatePostDate": [
            "April 20, 2018"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "April 18, 2018"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Tianjin Ever Union Biotechnology Co., Ltd."
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Beijing",
            "Beijing"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [
            "Chunting Li, doctor",
            "Zhengnan Li, master"
      ],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact",
            "Contact"
      ],
      "LocationCountry": [
            "China",
            "China"
      ],
      "LocationFacility": [
            "Peking University Third Hospital",
            "Tianjin Ever Union Biotechnology Co., Ltd."
      ],
      "LocationState": [],
      "LocationStatus": [],
      "LocationZip": [],
      "MaximumAge": [
            "60 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "A Randomized, Positive Controlled Trial That Assess the Safety And Efficacy of Umbilical Cord-Derived Mesenchymal Stem Cells in Moderate and Severe Plaque Psoriasis Patients"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Tianjin Ever Union Biotechnology Co., Ltd."
      ],
      "OrgStudyId": [
            "TianjinEverUnion"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [
            "DLQI score will be assessed at week 0,1,2,3,5,7,12,16,20,36,52",
            "Analysis the serum cytokine content, immunological subgroup and pathological section to explore the theoretical basis of stem cell therapy for psoriasis"
      ],
      "OtherOutcomeMeasure": [
            "Change from Baseline in Dermatology Life Quality Index (DLQI) score though 52 weeks",
            "Exploring the theoretical basis of stem cell therapy for psoriasis"
      ],
      "OtherOutcomeTimeFrame": [
            "Week 0,1,2,3,5,7,12,16,20,36,52",
            "0,1,2,3,5,7 12,16,20,36,52 week"
      ],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Peking University Third Hospital",
            "Peking University Third Hospital",
            "Peking University Third Hospital",
            "Peking University Third Hospital",
            "Peking University Third Hospital"
      ],
      "OverallOfficialName": [
            "Chunlei Zhang, doctor",
            "Xin Guan, doctor",
            "Chunting Li, doctor",
            "Jinzhu Guo, doctor",
            "Wenhui Wang, doctor"
      ],
      "OverallOfficialRole": [
            "Study Chair",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Study Director"
      ],
      "OverallStatus": [
            "Unknown status"
      ],
      "OversightHasDMC": [
            "No"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "September 30, 2018"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "The proportion of subjects who have a reduction of 75% or more from baseline in the psoriasis area-and-severity index score (PASI 75) at week 20",
            "The proportion of subjects who achieve a score of 0\uff08clear\uff09or 1\uff08almost clear\uff09on a 5-point Physician's global assessment\uff08PGA0/1) at week 20"
      ],
      "PrimaryOutcomeMeasure": [
            "Proportion of subjects who have 75% or more reduction in [Psoriasis area-and-severity index score (PASI)] (PASI75) at week 20",
            "Proportion of subjects who achieve a score of 0 or 1 on a 5-point Physician's global assessment\uff08PGA0/1) at week 20"
      ],
      "PrimaryOutcomeTimeFrame": [
            "Week 20",
            "Week 20"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "The proportion of subjects who have a reduction of 90% or more from baseline in the psoriasis area-and-severity index score (PASI 90) at week 20",
            "The proportion of subjects who have a reduction of 75% or more from baseline in the psoriasis area-and-severity index score (PASI 75) at week 12,16,36,52",
            "The proportion of subjects who achieve a score of 0\uff08clear\uff09or 1\uff08almost clear\uff09on a 5-point Physician's global assessment\uff08PGA0/1) at week 12,16,36,52",
            "Frequency of all Adverse Events (AEs) and Serious Adverse Events (SAEs) that occur during the whole trial including the observational period (AEs and SAEs include but not limited to headaches, allergies, fever and so on",
            "The proportion of subjects who experience a psoriasis relapse at any time until week 52. Psoriasis relapse is defined as loss of > 50% of the initial PASI improvement measured at week 7"
      ],
      "SecondaryOutcomeMeasure": [
            "Proportion of subjects who have 90% or more reduction in [Psoriasis area-and-severity index score (PASI)] (PASI90) at week 20",
            "Proportion of subjects who have 75% or more reduction in [Psoriasis area-and-severity index score (PASI)] (PASI75) at week 12,16,36,52",
            "Proportion of subjects who achieve a score of 0 or 1 on a 5-point Physician's global assessment\uff08PGA0/1) at week 12,16,36,52",
            "Frequency of Adverse Events and Serious Adverse Events",
            "Proportion of subjects who experience psoriasis relapse"
      ],
      "SecondaryOutcomeTimeFrame": [
            "Week 20",
            "Week 12,16,36,52",
            "Week 12,16,36,52",
            "Week 0 through week 52",
            "Week 8 though week 52"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "June 1, 2018"
      ],
      "StartDateType": [
            "Anticipated"
      ],
      "StatusVerifiedDate": [
            "December 2017"
      ],
      "StdAge": [
            "Adult"
      ],
      "StudyFirstPostDate": [
            "February 7, 2018"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "December 27, 2017"
      ],
      "StudyFirstSubmitQCDate": [
            "January 31, 2018"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}